A Double-Blind Randomized Controlled Trial of Augmentation and Switch Strategies for Refractory Social Anxiety Disorder
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Most patients remain symptomatic after an initial intervention with approved treatments for generalized social anxiety disorder. This randomized controlled trial provides systematic, prospectively derived data on the relative benefits of "next-step" pharmacotherapies to improve outcomes for individuals with generalized social anxiety disorder who remain symptomatic after initial treatment. METHOD: This three site, 12-week, double-blind randomized controlled trial compared the relative benefits of three strategies for patients remaining symptomatic (Liebowitz Social Anxiety Scale [LSAS] score >50) after a 10-week trial of sertraline alone: the addition of up to 3.0 mg/day of clonazepam (sertraline plus clonazepam), a switch to up to 225 mg/day of venlafaxine, or prolonged sertraline treatment with placebo (sertraline plus placebo). RESULTS: A total of 397 participants received at least one dose of sertraline; 181 nonresponders (LSAS score >50) at week 10 were randomly assigned to sertraline plus clonazepam, switch to venlafaxine, or sertraline plus placebo. Overall, 21% of patients achieved remission (LSAS score ≤30) at the endpoint, and 27% of patients assigned to sertraline plus clonazepam achieved remission compared with patients assigned to sertraline plus placebo (17%) or venlafaxine (19%), but the differences did not reach significance. Sertraline plus clonazepam was associated with a significantly greater drop in LSAS severity (p=0.020) and disability (p=0.0028) compared with sertraline plus placebo; no significant differences were observed on these parameters between venlafaxine and either sertraline plus placebo or sertraline plus clonazepam. In supplemental analysis, the overall response rate (LSAS score ≤50) was 46%, including a significantly greater proportion of patients in the sertraline plus clonazepam group (56%) compared with the sertraline plus placebo group responding (36%; p=0.027); differences did not reach significance between venlafaxine and sertraline plus placebo or sertraline plus clonazepam. CONCLUSIONS: The findings suggest that the clonazepam augmentation strategy provides relative benefits for sertraline nonresponders in social anxiety disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Stein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Self-citationPsychometric properties of the Liebowitz Social Anxiety Scale
HEIMBERG, R. G., HORNER, K. J., JUSTER, H. R., SAFREN, S. A., BROWN, E. J., SCHNEIER, F. R., & LIEBOWITZ, M. R. (1999) · Psychological Medicine · doi:10.1017/s0033291798007879 · Cited by 968 · cited 2×
“Inclusion criteria were 1) outpatients who were at least 18 years old with a current principal diagnosis of generalized social anxiety disorder by DSM-IV criteria (including designation by the patient as the most important source of distress or impairment), 2) a total score on the Liebowitz Social Anxiety Scale (LSAS)…”
BackgroundFRESCO, D. M., COLES, M. E., HEIMBERG, R. G., LIEBOWITZ, M. R., HAMI, S., STEIN, M. B., & GOETZ, D. (2001) · Psychological Medicine · doi:10.1017/s0033291701004056 · Cited by 874 · cited 1×
“It is possible that this concurrent information could have biased assessors in one way or another, but the reliance on the LSAS—essentially a clinicianelicitedpatient self-report of symptoms (19)—wouldmitigate this possibility.”
BackgroundSelf-citationSocial fears and social phobia in the USA: results from the National Comorbidity survey replication
Ruscio, A. M., Brown, T. A., Chiu, W. T., Sareen, J., Stein, M. B., & Kessler, R. C. (2008) · Psychological Medicine · doi:10.1017/s0033291707001699 · Cited by 835 · cited 2×
“The emotional and social costs of social anxiety disorder are considerable, with greater associated physical and emotional health difficulties, alcohol and drug abuse, suicide attempts, financial dependence, use of general medical resources, poorer marital functioning, and lower educational and vocational attainment a…”
BackgroundSelf-citationCognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
Mennin, D. S., Fresco, D. M., Heimberg, R. G., Schneier, F. R., Davies, S. O., & Liebowitz, M. R. (2002) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(02)00134-2 · Cited by 506
Cited by
Craske, M. G., & Stein, M. B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30381-6 · Cited by 640
Self-citationLeichsenring, F., & Leweke, F. (2017) · New England Journal of Medicine · doi:10.1056/nejmcp1614701 · Cited by 256
Bandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086295 · Cited by 158
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
The reappraisal of benzodiazepines in the treatment of anxiety and related disorders
Starcevic, V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.963057 · Cited by 90
“with sertraline to a 12-week treatment with sertraline plus clonazepam (up to 3 mg/day), sertraline plus placebo or venlafaxine [31].”
Method
Metadata
- Authors
- Pollack, M. H., Van Ameringen, M., Simon, N. M., Worthington, J. W., Hoge, E. A., Keshaviah, A., & Stein, M. B.
- Venue
- American Journal of Psychiatry
- Published
- 2014-01
- Volume
- 171
- Issue
- 1
- Pages
- 44-53
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2148075979
- Cited by
- 76
- References
- 9
- FWCI
- 12.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Double-Blind Randomized Controlled Trial of Augmentation and Switch Strategies for Refractory Social Anxiety Disorder. https://app.cochat.ai/papers/10.1176/appi.ajp.2013.12101353
- The paper
- Pollack, M. H., Van Ameringen, M., Simon, N. M., Worthington, J. W., Hoge, E. A., Keshaviah, A., & Stein, M. B. (2014). A Double-Blind Randomized Controlled Trial of Augmentation and Switch Strategies for Refractory Social Anxiety Disorder. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2013.12101353
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.